SIGN-UP NOW! SIGN-UP NOW! Click to become a VoiceAmerica Member for Free!
Voiceamerica radio logo
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

February 07th 2017:Non-Toxigenic Clostridium difficile 'NTCD-M3' For the Prevention and Treatment of C. difficile Infection -CDI

Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for "NTCD-M3." The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has

Read more
Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Guest Image

Dale Gerding, MD

Dr. Dale Gerding, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywod, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America and past Chair of the National and Global Public Health Committee and the Antibi
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 19/12/2017 10:00 19/12/2017 11:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for "NTCD-M3." The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has FDA Fast Track approval, is expected to be eligible for Breakthrough Therapy Designation by the FDA for a Phase 3 Clinical Trial, and to be eligible for Reference Product Exclusivity for 12 years for an approved biologics license application. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
GPlus Facebook Twitter Linkedin Social Media
presspass-banner